Eli Lilly (LLY) EBT Margin (2009 - 2026)
Eli Lilly posted quarterly EBT Margin of 44.7% for Q1 2026, up 1755.0% year-on-year from 2.41% in Q1 2025, and up 4.32% on a QoQ basis from 42.85% in Q4 2025.
Eli Lilly (LLY) has 18 years of EBT Margin data on file, last reported at 44.7% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 1755.0% year-over-year to 44.7%; the trailing twelve-month figure through Mar 2026 stood at 43.08% (up 1533.0% YoY), and the FY2025 full-year result was 39.48%, up 1133.0% from the prior year.
- EBT Margin for Q1 2026 stood at 44.7%, up from 42.85% in the prior quarter.
- Across five years, EBT Margin topped out at 44.7% in Q1 2026 and bottomed at 4.5% in Q3 2023.
- The 5-year median for EBT Margin is 27.15% (2025), against an average of 28.43%.
- The widest annual swing landed in 2023, when EBT Margin slumped 1805 bps; it then surged 2721 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 28.71% in 2022, then fell by 7 bps to 26.82% in 2023, then jumped by 39 bps to 37.23% in 2024, then climbed by 15 bps to 42.85% in 2025, then gained by 4 bps to 44.7% in 2026.
- The last three EBT Margin figures came in at 44.7% (Q1 2026), 42.85% (Q4 2025), and 41.09% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 44.70% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 24.89% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 6.93% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -21.49% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 24.18% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 37.07% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 135.53% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 28.20% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.70% |
| Dec 31, 2025 | 42.85% |
| Sep 30, 2025 | 41.09% |
| Jun 30, 2025 | 43.56% |
| Mar 31, 2025 | 27.15% |
| Dec 31, 2024 | 37.23% |
| Sep 30, 2024 | 13.89% |
| Jun 30, 2024 | 31.12% |
| Mar 31, 2024 | 28.92% |
| Dec 31, 2023 | 26.82% |
| Sep 30, 2023 | 4.50% |
| Jun 30, 2023 | 25.13% |
| Mar 31, 2023 | 21.98% |
| Dec 31, 2022 | 28.71% |
| Sep 30, 2022 | 22.55% |
| Jun 30, 2022 | 16.81% |
| Mar 31, 2022 | 26.29% |
| Dec 31, 2021 | 23.00% |
| Sep 30, 2021 | 18.39% |
| Jun 30, 2021 | 23.65% |
| Mar 31, 2021 | 21.69% |
| Dec 31, 2020 | 33.19% |
| Sep 30, 2020 | 25.04% |
| Jun 30, 2020 | 29.89% |
| Mar 31, 2020 | 28.67% |
| Dec 31, 2019 | 27.20% |
| Sep 30, 2019 | 25.67% |
| Jun 30, 2019 | 26.01% |
| Mar 31, 2019 | 14.36% |
| Dec 31, 2018 | 16.52% |
| Sep 30, 2018 | 25.27% |
| Jun 30, 2018 | 0.75% |
| Mar 31, 2018 | 27.51% |
| Dec 31, 2017 | 6.35% |
| Sep 30, 2017 | 10.46% |
| Jun 30, 2017 | 21.64% |
| Mar 31, 2017 | 1.17% |
| Dec 31, 2016 | 15.48% |
| Sep 30, 2016 | 18.70% |
| Jun 30, 2016 | 17.48% |
| Mar 31, 2016 | 11.65% |
| Dec 31, 2015 | 8.27% |
| Sep 30, 2015 | 21.13% |
| Jun 30, 2015 | 13.65% |
| Mar 31, 2015 | 13.30% |
| Dec 31, 2014 | 10.03% |
| Sep 30, 2014 | 13.44% |
| Jun 30, 2014 | 19.05% |
| Mar 31, 2014 | 19.02% |
| Dec 31, 2013 | 15.66% |
| Sep 30, 2013 | 26.22% |
| Jun 30, 2013 | 25.55% |
| Mar 31, 2013 | 34.83% |
| Dec 31, 2012 | 16.99% |
| Sep 30, 2012 | 34.44% |
| Jun 30, 2012 | 21.17% |
| Mar 31, 2012 | 23.84% |
| Dec 31, 2011 | 17.23% |
| Sep 30, 2011 | 24.44% |
| Jun 30, 2011 | 24.49% |
| Mar 31, 2011 | 21.82% |
| Dec 31, 2010 | 22.78% |
| Sep 30, 2010 | 30.46% |
| Jun 30, 2010 | 31.07% |
| Mar 31, 2010 | 31.13% |
| Dec 31, 2009 | 19.16% |
| Sep 30, 2009 | 19.86% |
| Jun 30, 2009 | 27.73% |
| Mar 31, 2009 | 33.35% |